Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.
Patritumab Deruxtecan Makes Headway in Early Phase Trials for Patients With Metastatic EGFR+ NSCLC and HER3+ Breast Cancer
Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.
ILD, Cardiotoxicities Move to the Forefront of Treatment-Related AE Management in Breast Cancer
Patricia Jakel, RN, MN, AOCN discusses adverse event management in the age of new breast cancer treatments.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
RWD Support Palbociclib Plus Aromatase Inhibitor Therapy for Elderly Patients With HR+/HER2– Metastatic Breast Cancer
Data from a retrospective analysis confirm the benefit of palbociclib plus an aromatase inhibitor in elderly patients with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer